Literature DB >> 27693183

Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis.

Petroula Proitsi1, Min Kim2, Luke Whiley2, Andrew Simmons3, Martina Sattlecker3, Latha Velayudhan4, Michelle K Lupton5, Hillka Soininen6, Iwona Kloszewska7, Patrizia Mecocci8, Magda Tsolaki9, Bruno Vellas10, Simon Lovestone11, John F Powell4, Richard J B Dobson12, Cristina Legido-Quigley2.   

Abstract

INTRODUCTION: The aim of this study was to (1) replicate previous associations between six blood lipids and Alzheimer's disease (AD) (Proitsi et al 2015) and (2) identify novel associations between lipids, clinical AD diagnosis, disease progression and brain atrophy (left/right hippocampus/entorhinal cortex).
METHODS: We performed untargeted lipidomic analysis on 148 AD and 152 elderly control plasma samples and used univariate and multivariate analysis methods.
RESULTS: We replicated our previous lipids associations and reported novel associations between lipids molecules and all phenotypes. A combination of 24 molecules classified AD patients with >70% accuracy in a test and a validation data set, and we identified lipid signatures that predicted disease progression (R2 = 0.10, test data set) and brain atrophy (R2 ≥ 0.14, all test data sets except left entorhinal cortex). We putatively identified a number of metabolic features including cholesteryl esters/triglycerides and phosphatidylcholines. DISCUSSION: Blood lipids are promising AD biomarkers that may lead to new treatment strategies.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Biomarkers; Brain atrophy; Classification; Dementia; Lipidomics; Machine learning; Metabolomics; Multivariate; Random forest; Rate of cognitive decline; sMRI

Mesh:

Substances:

Year:  2016        PMID: 27693183     DOI: 10.1016/j.jalz.2016.08.003

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  51 in total

1.  Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging.

Authors:  Marta Gonzalez-Freire; Ruin Moaddel; Kai Sun; Elisa Fabbri; Pingbo Zhang; Mohammed Khadeer; Norman Salem; Luigi Ferrucci; Richard D Semba
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-01-01       Impact factor: 6.053

Review 2.  Machine learning studies on major brain diseases: 5-year trends of 2014-2018.

Authors:  Koji Sakai; Kei Yamada
Journal:  Jpn J Radiol       Date:  2018-11-29       Impact factor: 2.374

3.  Human Plasma Metabolomics Study across All Stages of Age-Related Macular Degeneration Identifies Potential Lipid Biomarkers.

Authors:  Inês Laíns; Rachel S Kelly; John B Miller; Rufino Silva; Demetrios G Vavvas; Ivana K Kim; Joaquim N Murta; Jessica Lasky-Su; Joan W Miller; Deeba Husain
Journal:  Ophthalmology       Date:  2017-09-12       Impact factor: 12.079

4.  The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease.

Authors:  Jill K Morris; Brian D Piccolo; Kartik Shankar; John P Thyfault; Sean H Adams
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-12-26       Impact factor: 4.310

5.  Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.

Authors:  Qiushan Tao; Haihao Zhu; Xi Chen; Robert A Stern; Neil Kowall; Rhoda Au; Jan Krzysztof Blusztajn; Wei Qiao Qiu
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis.

Authors:  Zhiguang Huo; Lei Yu; Jingyun Yang; Yun Zhu; David A Bennett; Jinying Zhao
Journal:  Neurobiol Aging       Date:  2019-11-05       Impact factor: 4.673

Review 7.  Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review.

Authors:  Barry S Baumel; P Murali Doraiswamy; Marwan Sabbagh; Richard Wurtman
Journal:  Neurol Ther       Date:  2020-12-26

8.  Alteration in the Cerebrospinal Fluid Lipidome in Parkinson's Disease: A Post-Mortem Pilot Study.

Authors:  Joaquín Fernández-Irigoyen; Paz Cartas-Cejudo; Marta Iruarrizaga-Lejarreta; Enrique Santamaría
Journal:  Biomedicines       Date:  2021-04-29

9.  Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer's disease.

Authors:  Jodie Lord; Bradley Jermy; Rebecca Green; Andrew Wong; Jin Xu; Cristina Legido-Quigley; Richard Dobson; Marcus Richards; Petroula Proitsi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

Review 10.  A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.

Authors:  Steven J Kiddle; Nicola Voyle; Richard J B Dobson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.